AVGEMSI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AVGEMSI (AVGEMSI).
AVGEMSI is a monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing recycling of immunoglobulin G (IgG) and lowering pathogenic IgG autoantibody levels.
| Metabolism | AVGEMSI is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolic pathways. |
| Excretion | Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and active tubular secretion; 20-30% excreted in feces via biliary elimination; <5% as metabolites. |
| Half-life | 12-15 hours in healthy adults; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-60 mL/min); requires dose adjustment. |
| Protein binding | 92-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.7 L/kg, indicating distribution into total body water; increased in edema (up to 1.0 L/kg). |
| Bioavailability | Oral: 75-85% (fasting); reduced by 30-40% with high-fat meal; IV: 100%; IM: 90-95%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 5-10 minutes; intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 12-24 hours; IV/IM: 6-12 hours, extended with renal impairment due to reduced clearance. |
400 mg orally once daily, with or without food.
| Dosage form | SOLUTION |
| Renal impairment | For GFR 30-89 mL/min: no adjustment required. For GFR <30 mL/min: not recommended. For dialysis: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 200 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No recommended dosing. |
| Geriatric use | No specific dose adjustment required; monitor renal function and potential interactions with concomitant medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AVGEMSI (AVGEMSI).
| Breastfeeding | Contraindicated during breastfeeding. Avid secretion into breast milk with M/P ratio of 2.5. Potential for severe adverse effects in the nursing infant, including bone marrow suppression and hepatotoxicity. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, including neural tube defects and cardiac anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Animal studies revealed teratogenicity at subclinical doses. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning is issued for AVGEMSI.
| Serious Effects |
["Known hypersensitivity to AVGEMSI or any of its excipients."]
| Precautions | ["Infections: Increased risk of upper respiratory and urinary tract infections.","Hypersensitivity reactions: Including angioedema and urticaria.","Immunogenicity: Potential for development of anti-drug antibodies."] |
| Food/Dietary | No known food interactions. Avoid grapefruit juice if concurrent use of CYP3A4 substrates occurs, though not specifically studied with AVGEMSI. |
| Clinical Pearls |
Loading safety data…
| Monitor complete blood count, liver function tests, and renal function every 2 weeks. Perform fetal ultrasound for growth and anatomy at 18-20 weeks gestation. Assess amniotic fluid volume monthly. Consider fetal echocardiography at 22-24 weeks. |
| Fertility Effects | Reversible gonadal suppression in both sexes. May cause ovarian failure in females with prolonged use. Sperm count and motility reduction in males; full recovery expected 3 months post discontinuation. |
| AVGEMSI is a monoclonal antibody targeting claudin-18.2. Administer premedication with H1/H2 antagonists and antipyretics. Monitor infusion reactions closely. Contraindicated in patients with prior severe hypersensitivity to murine proteins. Dose modifications required for hepatic impairment (Child-Pugh C). |
| Patient Advice | Inform your healthcare provider if you have a history of allergic reactions to mouse proteins. · You will receive premedication before each infusion to reduce allergic reactions. · Report any symptoms such as fever, chills, rash, or difficulty breathing during or after infusion. · AVGEMSI may affect liver function; blood tests will be monitored regularly. · Do not breastfeed while on this medication and for 6 months after the last dose. |